Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828289 | 0.84 | ADH5 (0.51) | NSD2SLC22A12 | |
| SCHEMBL1829684 | 0.83 | HRH2 (0.45) | HRH2HRH1FFAR1MMP2 | |
| SCHEMBL1828357 | 0.75 | GRM2 (0.42) | HRH2HRH1NSD2KDM1AEGLN2 | |
| SCHEMBL17629909 | 0.74 | MAOA (0.43) | HRH2HRH1KDM1AEGLN2 | |
| SCHEMBL1829979 | 0.71 | HRH2 (0.40) | HRH2HRH1NSD2EGLN2 | |
| SCHEMBL1829774 | 0.69 | HRH2 (0.41) | HRH2HRH1FFAR1GAA | |
| SCHEMBL1828544 | 0.69 | AR (0.41) | HRH2HRH1KDM1AEGLN2 | |
| SCHEMBL1828903 | 0.68 | GRM2 (0.38) | HRH2HRH1SLC22A12 | |
| SCHEMBL1829683 | 0.67 | HRH2 (0.44) | HRH2HRH1 | |
| SCHEMBL12556740 | 0.67 | MEN1 (0.54) | GAACNKSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-8642628-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2315590-B1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS LLC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | HRH2 3574/4885HRH1 4245/4885FFAR1 1480/4885 |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | HRH2 3574/4885HRH1 4245/4885FFAR1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.